ID
24570
Beschrijving
Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive
Trefwoorden
Versies (1)
- 06-08-17 06-08-17 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
6 augustus 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
Beschrijving
If "yes" to COPD exacerbation, record following items.
Alias
- UMLS CUI-1
- C0740304
Beschrijving
date of onset of COPD exacerbation
Datatype
date
Alias
- UMLS CUI [1,1]
- C0574845
- UMLS CUI [1,2]
- C0740304
Beschrijving
outcome of COPD exacerbation
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0085565
- UMLS CUI [1,2]
- C0740304
Beschrijving
date of resolution or death
Datatype
date
Alias
- UMLS CUI [1]
- C2985858
- UMLS CUI [2]
- C1148348
Beschrijving
severity of COPD excerbation
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0439793
- UMLS CUI [1,2]
- C0740304
Beschrijving
Subjects who experience more than one moderate exacerbation requiring antibiotic and/or oral corticosteroid treatment during the treatment period and/or experience a severe exacerbation requiring hospitalisation during the course of the study must be withdrawn.
Datatype
text
Alias
- UMLS CUI [1,1]
- C0422727
- UMLS CUI [1,2]
- C0740304
Similar models
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
C0740304 (UMLS CUI [1,2])
C0740304 (UMLS CUI [1,2])
C1148348 (UMLS CUI [2])
C0740304 (UMLS CUI [1,2])
C0740304 (UMLS CUI [1,2])